You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK)首季純利升26.9%至14.72億元 抗腫瘤收入增逾二成
格隆匯 05-24 12:19

格隆匯5月24日丨石藥集團(01093.HK)公佈,截至2021年3月31日止3個月,集團實現收入總額67.34億元人民幣(單位下同),同比增長9.9%;基礎溢利14.72億元,同比增長63.3%;股東應占溢利14.72億元,同比增長26.9%;每股基本盈利12.29分。

成藥業務

在醫藥行業改革深化及市場競爭加劇的經營環境下,集團繼續採取專業學術推廣、醫院開拓、市場下沉、臨牀應用範圍拓展、專業銷售隊伍擴大等措施,推動成藥業務的持續增長。於2021年第一季,成藥業務錄得銷售收入54.8億元,較去年同期增加9.1%,實現穩定的增長。

神經系統疾病產品:主要產品包括恩必普(丁苯酞軟膠囊及丁苯酞氯化鈉注射液)、歐來寧(奧拉西坦膠囊及注射用奧拉西坦)、舒安靈(己酮可可鹼緩釋片及己酮可可鹼注射液)、恩悉(鹽酸普拉克索片)及歐來妥(鹽酸美金剛片)。於期內,神經系統疾病產品錄得銷售收入17.95億元,同比增加8.5%,其中恩必普的銷售收入增加8.7%、舒安靈增加647.5%。

抗腫瘤產品:主要產品包括多美素(鹽酸多柔比星脂質體注射液)、津優力(聚乙二醇化重組人粒細胞刺激因子注射液)、克艾力(注射用紫杉醇白(蛋白結合型))及萬可達(注射用硼替佐米)。於期內,抗腫瘤產品錄得銷售收入18.69億元,同比增加20.4%,其中多美素的銷售收入增加60.1%、克艾力增加8.4%(銷量增加252%,去年同期的產品價格為集採結果執行前的價格)、津優力增加2.3%。抗感染產品:主要產品包括舒羅克(注射用美羅培南)、諾莫靈(阿莫西林膠囊)、先曲╱石藥(注射用頭孢曲松鈉)、中諾立新(注射用頭孢呋辛鈉)、新維宏(阿奇黴素片)、維宏(阿奇黴素分散片╱膠囊╱腸溶片)。於期內,抗感染產品錄得銷售收入7.01億元。

原料產品業務

受惠於產品價格上升,維生素C產品於期內錄得銷售收入5.24億元,較去年同期增加22.9%。抗生素及其它產品的銷售收入亦因銷量上升增加31%至3.89億元。

功能食品及其它業務

該業務於期內錄得銷售收入3.41億元。

報吿期內的研發費用達6.91億元(計入損益表中),同比增加21.7%,約佔成藥業務收入的12.6%。目前在研項目約300個,其中小分子創新藥40餘項、大分子創新藥40餘項,新型製劑20餘項,主要聚焦於腫瘤、自身免疫、精神神經、消化和代謝、心腦血管系統及抗感染治療領域。目前有30個產品處於藥品註冊審評待批階段,39個產品正在開展臨牀試驗(包括31個創新藥以及8個新型製劑),以及5個產品待批臨牀批件。

未來三年,集團預計將上市新產品60餘個,其中預計市場空間超過10億元的重磅品種將不少於15個,而納米技術平台研發的米託蒽醌脂質體、多西他賽白蛋白納米粒、紫杉醇白蛋白納米粒(速溶)等產品,都是具有全球專利及極具市場價值的重磅產品。這些產品的上市必將強力支撐集團未來的高質量增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account